FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

MARTIN H. COHEN, YUAN LI SHEN, PATRICIA KEEGAN, RICHARD PAZDUR

The Oncologist 2009;14:1131–1138; doi: 10.1634/theoncologist.2009-0121

On page 1134, “serum glutamic oxaloacetic transaminase” was incorrectly expressed as “serum glutamic oraloacetic transaminase”. In addition, the enzyme level was shown as 1.5.0; it should have been 1.5. The publisher regrets these errors.